Literature DB >> 9595509

Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension?

A Franco-Cereceda1, P Holm.   

Abstract

We evaluated the hemodynamic effects of various endothelin (ET) receptor antagonists using selective and non-selective ETA and ETB receptor blockade in hypoxic pigs in vivo. BMS-182874 (10 mg/kg i.v.) TBC-11251z (10 mg/kg i.v.), selective ETA receptor antagonists, attenuated hypoxia (FiO2 0.1)-evoked increase in pulmonary arterial pressure and pulmonary vascular resistance. Bosentan (10 mg/kg i.v.) a non-selective ETA and ETB receptor antagonist, cause essentially similar effects as ETA antagonism alone. No effects were observed after selective ETB blockade using BQ-788 (total dose 1 mg i.v.). The vasoconstrictor effect of exogenous ET was most effectively antagonized by TBC-11251z, followed by BMS-182874 and bosentan. The pulmonary vasodilator effect exerted by exogenous ET during hypoxia was reversed by BQ-788 and bosentan but not by TBC-11251z or BMS-182874. We can therefore conclude that ET contributes to hypoxic pulmonary vasoconstriction primarily through ETA receptor activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9595509     DOI: 10.1097/00005344-199800001-00128

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

Review 2.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.